News

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...
in the January to March period by 9 percent to P16.6 billion, with the company already expecting to exceed its full-year earnings record. BPI president Jose Teodoro Limcaoco confirmed to reporters ...
MANILA, Philippines — The country’s total outstanding debt climbed to a fresh high of P16.68 trillion as of end-March, 12 percent higher than last year’s P14.93 trillion, the Bureau of the ...
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer Doxorubicin plus trabectedin followed by trabectedin maintenance showed a survival advantage ...
CDK4/6 inhibitor Verzenio (abemaciclib) was the third drug in the class to reach the market, first approved in 2017 as a second-line treatment for post-menopausal patients with hormone receptor ...
Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms ...
A daily pill, Kisqali is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that prevents cancer cells from dividing and growing. This kind of drug is taken with an aromatase inhibitor ...
In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.
Meihua Li and Apeng Liang contributed equally to this work. FDA approved CDK4/6 inhibition medicines has demonstrated significant clinical benefits in patients with HR+/HER2- breast cancer. However, ...
CDK4/6 inhibitors have been approved for the treatment of metastatic ER+ and HER2- breast cancer. However, patients will become resistance due to various mechanisms, resulting in high unmet need.